Rapid encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura
Related Experiment Video
Updated: Jun 28, 2026

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
Sunitha Golla1, Clare Horkan, Grigore Dogaru
1Department of Medicine, MetroWest Medical Center, Framingham, Mass., USA.
Rho (D) immune globulin intravenous (IV RhIG, WinRho SDF) has been shown to be a safe treatment for idiopathic thrombocytopenic purpura. Common side effects of IV RhIG include mild hemolysis, febrile reaction and headache. Significant hemolysis with renal impairment is infrequently noted. A single case of irreversible encephalopathy following IV RhIG has been reported. We report a second case of encephalopathy following an infusion of IV RhIG for treatment of idiopathic thrombocytopenic purpura.
Rho (D) immune globulin intravenous (IV RhIG, WinRho SDF) has been shown to be a safe treatment for idiopathic thrombocytopenic purpura. Common side effects of IV RhIG include mild hemolysis, febrile reaction and headache. Significant hemolysis with renal impairment is infrequently noted. A single case of irreversible encephalopathy following IV RhIG has been reported. We report a second case of encephalopathy following an infusion of IV RhIG for treatment of idiopathic thrombocytopenic purpura.
Related Concept Videos
Encephalitis ll: Pathophysiology
Encephalitis l: Introduction
Diphtheria
Hepatic Encephalopathy
Rocky Mountain Spotted Fever
Arboviral Encephalitis

